Epidemiologic data shows that higher levels of high-density lipoprotein cholesterol HDL-C and lower levels of low-density lipoprotein cholesterol LDL-C are associated with less atherosclerosis and lower risk for major heart problems. Evacetrapib (LY2484595) has demonstrated ability to increase (HDL-C) and decrease (LDL-C). The primary objective of this study is to test the hypothesis that evacetrapid 130 mg daily, comparison to a placebo, reduces the incidence of the composite endpoint of cardiovascular (CV) death, myocardial infarction (heart attack or MI), stroke or other cardiovascular conditions. In addition, testing the hypotheses that evacetrapib 130 mg daily increases high-density lipoprotein-cholesterol (HDL-C) and decreases low-density lipoprotein-cholesterol (LDL-C) at 3 months after randomization.
Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at High Risk for Vascular Outcomes (The ACCELERATE study)
099-12Principal Investigator: Conducted at:
Long Beach MemorialCurrently enrolling additional patients: